This study was a randomized double-blind, placebo-controlled trial to evaluate the efficacy of bupropion (300 mg per day, total N=540) in African American light smokers (24). Eligibility criteria were similar to Study 1 and included exclusion based on contraindication of bupropion use. Bupropion use lasted 7 weeks and HE counseling was similar to Study 1. The participants were followed for a total of 26 weeks (6 month). Both studies were approved by the University of Kansas Human Subject Committee, the University of Toronto Ethics Review Office, and the University of California San Francisco Human Research Protection Program.
